Nivolumab + Relatlimab

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Microsatellite Stable (MSS) Colorectal Adenocarcinomas

Conditions

Microsatellite Stable (MSS) Colorectal Adenocarcinomas, Colorectal Adenocarcinoma

Trial Timeline

Feb 12, 2019 → Sep 18, 2024

NCT ID

NCT03642067

About Nivolumab + Relatlimab

Nivolumab + Relatlimab is a phase 2 stage product being developed by Bristol Myers Squibb for Microsatellite Stable (MSS) Colorectal Adenocarcinomas. The current trial status is completed. This product is registered under clinical trial identifier NCT03642067. Target conditions include Microsatellite Stable (MSS) Colorectal Adenocarcinomas, Colorectal Adenocarcinoma.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (8)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07459543	Approved	Recruiting	Nov 15, 2026	May 28, 2029	Untreated Melanoma
NCT06237920	Phase 2	Recruiting	Feb 19, 2024	Aug 1, 2028	Urologic Neoplasms
NCT04658147	Phase 1	Active	May 28, 2021	Jun 1, 2030	Hepatocellular Carcinoma
NCT04567615	Phase 2	Completed	Feb 4, 2021	Nov 19, 2025	Hepatocellular Carcinoma
NCT04552223	Phase 2	Completed	Nov 10, 2020	Jan 4, 2026	Metastatic Uveal Melanoma
NCT03623854	Phase 2	Completed	Apr 3, 2019	Sep 28, 2023	Chordoma
NCT03610711	Phase 1/2	Active	Mar 6, 2019	Dec 1, 2026	Gastroesophageal Cancer
NCT03642067	Phase 2	Completed	Feb 12, 2019	Sep 18, 2024	Microsatellite Stable (MSS) Colorectal Adenocarcinomas

Competing Products

11 competing products in Microsatellite Stable (MSS) Colorectal Adenocarcinomas

See all competitors

Product	Company	Stage	Hype Score
eFT508 + Avelumab	eFFECTOR Therapeutics	Phase 2	44
Evorpacept (ALX148) + Cetuximab + Pembrolizumab	Eli Lilly	Phase 2	52
grapiprant + grapiprant and pembrolizumab	Merck	Phase 1	33
Bevacizumab + Capecitabine + Pembrolizumab	Merck	Phase 2	52
MK-3475 + INCB024360	Merck	Phase 1/2	41
AMG 436	Amgen	Phase 1	32
Nivolumab + Ipilimumab	Bristol Myers Squibb	Phase 2	51
Nivolumab + Ipilimumab	Bristol Myers Squibb	Phase 2	51
Copanlisib + Nivolumab	Bristol Myers Squibb	Phase 1/2	40
Ipilimumab + Nivolumab + Cobimetinib + Daratumumab + BMS-986016	Bristol Myers Squibb	Phase 2	51
Balstilimab + Botensilimab	Agenus	Phase 2	44

Other Products from Bristol Myers Squibb

DeucravacitinibApproved

Aripiprazole + Olanzapine + HaloperidolApproved

Irbesartan + CiprofibrateApproved

Entecavir + Lamivudine Placebo + Lamivudine + Entecavir PlaceboApproved

deucravacitinibApproved